A new study finds a new treatment option for a condition affecting 6 million Americans.
According to a recent University of Virginia (UVA) health study, Colchine, a common gut medicine, dramatically increased patient survival rates due to heart failure. In individuals who accumulate cholesterol in their arteries, researchers believe that colchine may also reduce the risk of heart attacks and stroke.
Between March 2011 and February 2020, more than 1,000 patients were hospitalized for heart failure at the University of Virginia Medical Center after a record review. Patients who experienced gout flare had a survival rate of 97.9%, as opposed to patients who did not receive colchisene, whose survival rate was 93.5%.
“These findings highlight the importance of novel inflammatory procedures in heart failure,” said Kenneth Balchick, MD, MS, cardiologist and clinical investigator at UVA. The indication of benefit with Colchine in these patients was very impressive, and I expect these findings to have a significant impact on medical care in future research for heart failure and patients with the condition
“Heart failure is more likely than heart’s pumping function failure. There are other processes involved, especially during the intense stage of hospitalization such as elevated inflammation and neurohormonal processes. “Many therapeutic agents for heart failure target neurohormonal pathways, but if any targets are inflammatory pathways,” said Sola Mazemba, MPH, of the UVA School of Medicine specializing in heart failure. Researcher and specialist of heart diseases. “Calchine is a drug with anti-inflammatory properties that could potentially reduce the acute inflammation we see in patients hospitalized with heart failure”
Sola Mazemba, MD, MPH, UVA Health and UVA School of Medicine is a Heart Failure Specialist. Credit : Yuvi Health
Treatment of gout and heart failure
Heart failure occurs when the ability to pump blood in the body fails. According to the American Heart Association, nearly 6 million Americans suffer from heart failure, and the condition is responsible for more than 86,000 deaths each year.
Gout, a type of arthritis that features the construction of uric acid crystals in joints, is common in heart failure patients. Colchisin, steroids, and nonsteridal anti-inflammatory drugs (NSAIDs) are common treatments for heart failure and ibuprofen gout, although there is a tendency to increase heart failure symptoms commonly used steroids and NSAIDs Not are given.
Although a well-established treatment for colchine gout, the UVA research team believes the drug’s anti-inflammatory properties could prove key to improving outcomes for heart failure patients. They think colchine can reverse inflammation of the heart and blood vessels with the ability to improve outcomes, especially in the extreme stages of hospitalization for heart failure.
Additional, larger studies are needed to further discover colchine as a potential treatment option for heart failure, but UVA researchers are encouraged by their preliminary findings.
“We’re very excited about these results, especially considering that Colchine is already a widely available medicine,” Mary E. said. Ruth, Pharm D, Researcher and Cardiovascular Pharmacist at UVA Health. If additional studies confirm results, Colchine may be another tool we can use to improve the survival of our heart failure patients.
The work was funded by the National Health Organization, Grant R01 HL159945, and by the American Heart Association,
Reference: Association of Colchine Use for Severe Gout with Severe Gout “by Mary E”. Ruth, Melissa E. Chin , Steven P. Done, Kenneth C. Balchik and Sola Mazemba, 28 April 2022, Clinical Cardiology.